Merit raises earnings guidance and discloses its completed Solo Pace acquisition
Merit Medical ($MMSI) raised its 2026 adjusted EPS forecast to $4.33–$4.37 from $4.25–$4.35 after third-quarter 2026 revenue increased 8.4% to $416.2 million. Organic growth at constant currency was 9%. Adjusted quarterly EPS rose 22% to $1.12, while reported EPS reached $0.70. The annual revenue range narrowed to $1.635–$1.642 billion, with a modestly higher midpoint. Merit also disclosed that it had completed the purchase of Solo Pace’s remaining equity for approximately $45 million. It previo
0